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Abstract
Objective: To assess the cost effectiveness of giving tranexamic acid (TXA) to bleeding trauma patients in low, middle and
high income settings.
Methods: The CRASH-2 trial showed that TXA administration reduces the risk of death in bleeding trauma patients with a
small but statistically significant increase in non-intensive care stay. A Markov model was used to assess the cost
effectiveness of TXA in Tanzania, India and the United Kingdom (UK). The health outcome was the number of life years
gained (LYs). Two costs were considered: the cost of administering TXA and the cost of additional days in hospital. Cost data
were obtained from hospitals, World Health Organization (WHO) database and UK reference costs. Cost-effectiveness was
measured in international dollars ($) per LY. Both deterministic and probabilistic sensitivity analyses were performed to test
the robustness of the results to model assumptions.
Findings: Administering TXA to bleeding trauma patients within three hours of injury saved an estimated 372, 315 and 755
LYs per 1,000 trauma patients in Tanzania, India and the UK respectively. The cost of giving TXA to 1,000 patients was
$17,483 in Tanzania, $19,550 in India and $30,830 in the UK. The incremental cost of giving TXA versus not giving TXA was
$18,025 in Tanzania, $20,670 in India and $48,002 in the UK. The estimated incremental cost per LY gained of administering
TXA is $48, $66 and $64 in Tanzania, India and the UK respectively.
Conclusion: Early administration of TXA to bleeding trauma patients is likely to be highly cost effective in low, middle and
high income settings.
Trial Registration: This paper uses data collected by the CRASH 2 trial: Controlled-Trials.com ISRCTN86750102, Clinicaltrials.
gov NCT00375258 and South African Clinical Trial Register DOH-27-0607-1919.
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Introduction
The CRASH-2 trial showed that giving TXA to bleeding
trauma patients results in a statistically significant and clinically
important reduction in all-cause mortality (RR=0.91, 95% CI
0.85 to 0.97), with no apparent increased risk of vascular occlusive
events [1]. The trial inclusion criteria were clinical and did not
depend on the results of laboratory tests. Patients were enrolled if
they were judged by the doctor to have on-going significant
haemorrhage, as evidenced by low blood pressure and a fast pulse,
or if they were considered to be at risk of significant haemorrhage,
for example, patients with compensated haemorrhage and stable
vital signs, or those in whom bleeding might have stopped but who
might start bleeding again following resuscitation. Further analyses
have shown that the beneficial effects of TXA depend on the
promptness with which TXA treatment is initiated. Early
treatment, within about three hours of injury, appears to be more
effective than later treatment. If administered within three hours
TXA reduces the risk of death by 13% (RR=0.87, 95% CI 0.81
to 0.95), while if TXA is administered after three hours it is not
effective and can even been harmful [1].
On the basis of the CRASH-2 trial results, it has been estimated
that the widespread use of TXA could save between 70,000 and
100,000 lives per year around the world. Because over 90% of
trauma deaths are in low and middle income countries the
potential for TXA to save lives is particularly high in these settings
[2]. Nevertheless, TXA is unavailable in many low and middle
income countries. Indeed, some hospitals in Africa that took part
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routine clinical use. In high income countries, due to the low cost
of the intervention, TXA is likely to be highly cost effective.
Although TXA is relatively inexpensive, evidence on the cost
effectivenessofTXAintraumaisanimportantfactorinthe decision
to include TXA on the WHO list of essential medicines. Economic
evaluations of TXA in elective surgery show that TXA is a cost-
saving intervention [3,4]. A recent study of the cost effectiveness of
TXA in four Sub-Saharan countries shows that in countries where
there is either a shortage of blood, or where blood is not properly
screened, TXA can reduce mortality. In countries where blood is
available, TXA can reduce blood borne infections [4].
The objective of the present study is to assess the cost
effectiveness of giving TXA to bleeding trauma patients. The cost
of TXA and its effectiveness will vary between countries. In Low
Income Countries (LICs), TXA is likely to cost less than in High
Income Countries (HICs) because both administration cost and
cost per day in a general ward are lower. However, in both LICs
and Middle Income Countries (MICs) life expectancies are shorter
and there will be a lower number of life years gained per patient.
Using World Bank country classification criteria, the cost
effectiveness of TXA was evaluated in three countries: Tanzania
(LIC with Gross Domestic Product (GDP) per capita $509); India
(MIC with GDP per capita $1,134); and the UK (HIC with GDP
per capita $35,165) [5]. Tanzania was chosen in order to assess the
cost-effectiveness of TXA when income per capita and life
expectancy are low [6,7]. India was selected because it is one of
the MICs where TXA can avert the highest number of trauma
deaths [2]. The UK was selected because within HICs it has an
average GDP per capita and life expectancy.
Materials and Methods
An economic evaluation was carried out to investigate the cost-
effectiveness of administering TXA for the treatment of significant
haemorrhage following trauma. Cost-effectiveness was measured
by the incremental cost per life-year gained. The life-years gained
are estimated from a simple Markov model where patients are
either alive or dead, and by comparing the life-years experienced
by a cohort who are given TXA with one that does not receive
TXA. The model has an annual cycle and a lifetime horizon.
Transitions between alive and dead in the first year are estimated
from the CRASH-2 data, and in subsequent years from life tables.
Life-years gained were discounted using an annual rate of 3.5%.
The model was developed in Excel and STATA 11 software was
used for the statistical analysis.
The cumulative risk of death during the first year in the placebo
arm was estimated using CRASH 2 data. After the first year,
patients were assumed to experience the same probability of death
as the general population of a similar age, estimated using country
specific life tables from WHO [8]. Assuming that TXA is
administered within three hours (because after this time it is
unlikely to be effective), the risk of death in the first year after
trauma in the intervention group was calculated by multiplying the
baseline cumulative hazard of the placebo group by the relative
risk reduction of all cause mortality estimated in the CRASH-2
trial (RR=0.87, 95% CI 0.81 to 0.95) [2]. Beyond twelve months
the risk of death in the intervention arm was assumed to be equal
to the one estimated for the placebo arm.
Since the CRASH-2 trial recorded data up to 28 days or death,
a parametric survival function was fitted to extrapolate mortality
experience over the twelve months following injury. Different
parametric survival functions (Weibull, Gompertz, log-logistic, log-
normal and generalised gamma) were compared using the Akaike
Information Criterion (AIC), and Cox-Snell residuals were plotted
as a confirmatory test [9]. The Gompertz model provided the best
fit to the data. The Gompertz generic survival function is [9]:
St ðÞ ~exp {c1l ect{1 ðÞ
 {
Where t is the time-frame over which the cumulative probability of
survival is estimated, c is an ancillary parameter that determines
whether the hazard of death increases over time (if c is positive) or
decreases (if c is negative). When covariates are considered in the
analysis l is given by the following equation [9]:
l~exp constzx1b1zx2b2zx3b3 ðÞ
If data from the CRASH-2 trial are used the formula reported
above becomes:
St ðÞ ~exp {{ 0:20 ðÞ
{1l exp{0:20t{1
 
c (20.20, 95% CI 20.21 to 20.18) is negative meaning that after
trauma the hazard rate decreases over time. Age, gender and GDP
group were explored as covariates in the Gompertz model. A GDP
per capita was assigned to each country in the trial according to
the latest World Bank estimates and two binary variables, X2 and
X3 were constructed to estimate whether the likelihood of death
changes according to the GDP [6]. X2 took the value 1 for LICs
and 0 otherwise. Similarly X3 took the value of 1 for MICs and 0
otherwise. As expected the baseline probability of death increases
with age (age coefficient=0.020, 95% CI 0.016 to 0.024) while
gender was not found to be statistically significant (20.06, 95%
CI-0.22 to 0.11). Both GDP coefficients were found to be highly
significant (b2=20.31; b3=20.61).
Thus, the function for l is:
l~exp {4:26z0:020|Age{0:31|LIC{0:61|MIC ðÞ
Since the number of life-years saved will depend in part on the age
of the patient, the aggregate effect across all trauma victims was
estimated by first running the model for different age groups, and
then calculating the average result. Five age groups were identified
each representing a similar proportion of the total trial
participants: 16 to 20 years; 21 to 25 years; 26 to 34; 35 to 50;
and more than 50 years. Patients in each group were assigned a
starting age equal to the mean observed for that age group in the
trial. The cumulative hazard rate, the probability of death in the
first year after trauma, was estimated for each of these five mean
ages. The overall number of life years saved in each country was
then calculated as a weighted average of the results for the five age
groups using the age distribution for trial participants in countries
of the relevant income group.
Figure 1 shows the extrapolated hazard rate function during the
first fifty days after trauma modelled from the observed 28 day
data for the placebo group in the trial. The modelled hazard rate
decreases to almost zero in the first 28 days after hospital
admission and then remains constant. This finding is consistent
with previous studies suggesting that the majority of trauma-
related deaths occur within a few weeks after injury. The figure
also validates the model assumption that after one year the
baseline risk of death is the same observed in the general
population [10].
The incremental cost of TXA versus no TXA was calculated
from a health service perspective [11]. Two cost items were
CEA of TXA in Trauma
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bleeding trauma patients and the incremental cost of non-intensive
care hospital stay. Given that costs associated with TXA
administration occur within one year post trauma, costs were
not discounted. Costs have been converted from national
currencies into international dollars ($) using Purchasing Power
Parities (PPPs) [12].
In the main analysis, the cost of TXA ($5.70 per g) was taken
from the British National Formulary and converted into
international dollars [13,14]. The same price was assumed for
Tanzania and India in the absence of recent studies reporting the
cost of TXA. The influence of different drug prices on the cost
effectiveness of TXA was explored in one way and probabilistic
sensitivity analyses. A dose of 2 g (1 g loading dose and 1 g
maintenance dose) has been assumed as per the CRASH-2 trial
protocol [2]. The CRASH-2 trial investigators estimate that the
nursing time required to administer TXA ranges between 10–
60 minutes. In Tanzania, a nurse’s salary depends on both rank
and on the location of the hospital. It can range between $800 per
month, for a principal nursing officer, to $300 per month, for a
newly started nurse (2008-9 prices) [15]. For the analysis, an
average salary of $450 per month, which is the salary of a nursing
officer, is assumed [15]. Using this estimate the average cost per
hour was estimated to be $2.40 (range:$1.60–$4.20) [15,16]. The
average salary for a nurse in India varies by type of employer.
Nurses working in public hospitals earn on average 30,000Rs
($2,044) per month while nurses employed in the private sector
have a salary ranging between 7,000 and 10,500Rs per month
($480–$720) [17,18,19]. Assuming that a nurse works an average
of 37.5 hours per week, the average cost per hour of a nurse in
India was assumed to be $8.08 (range: $2.83–$14.06). In the UK,
the average cost per hour of a nurse is $38 [13,20]. The
disposables used for TXA administration are two 10 ml syringes,
two green needles, two bags of saline (100 ml and 500 ml for
loading and maintenance doses respectively) and an IV adminis-
tration set [21]. The cost of a syringe and needle was obtained
from the study by Dziekan et al. [22] who estimated the average
unit cost of syringes and needles in different regions of the world.
The cost of saline and an IV administration set was obtained from
the British National Formulary and converted into international
dollars [14]. Storage and distribution costs per intervention are
negligible. The overall cost of administering TXA per patient is
estimated to be: $17.48; $19.55; and $30.83 in Tanzania, India
and the UK respectively.
The improvement in survival following administration of TXA
in the CRASH-2 trial was associated with a slight increase in the
number of days spent in non-ICU hospital facilities (mean
difference=0.04, 95% CI 0.007 to 0.08, p=0.0095). Since the
incremental cost of non-ICU days associated with TXA will vary
between countries, the mean length of stay of CRASH-2 patients
in the placebo arm was calculated for low, middle and high
income countries. As reported in Table 1, LICs patients tend to
stay longer in the hospital.
Table 1 shows the unit cost of a non-ICU day. For Tanzania
and India these were taken from WHO-CHOICE and uplifted to
2008-9 estimates, while for UK they were taken from Reference
Costs [23,24,25,26]. When more than one cost estimate was
available per country, the average was used.
Sensitivity analysis
One way sensitivity analysis was undertaken in order to assess
the impact of uncertainty regarding the input parameters. The
incremental cost per life year saved for TXA versus no TXA was
estimated for different values of the RR of death with TXA (95%
CI 0.81 to 0.95) [2] . One way sensitivity analysis was also
conducted on the increase in non-ICU hospital stay following
TXA administration (95% CI 0.007 to 0.08).
Due to the low cost of labour in both Tanzania and India, the
drug cost constitutes almost 70% of the overall intervention cost. A
cost-effectiveness analysisconducted byCasatietal. (1999)estimated
that TXA would cost $2.57 per g, while a study conducted recently
in India reported that TXA administration would cost $6.60 per g
[27,28]. In order to account for price variability between countries
Figure 1. Hazard rate following trauma.
doi:10.1371/journal.pone.0018987.g001
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ranging between $2.57, from the Casati et al. study, and $45.67
estimated by Eaton et al. [29]. Finally one-way sensitivity analysis
was performed to estimate how the TXA cost effectiveness changes
according to different estimates of the cost of a non-ICU day. The
lowest estimates, for both Tanzania and India , were the cost per
day in a primary health centre ($9.84 and $18.75 respectively) while
the highest estimates ($18.69 and $35.41) were obtained from
tertiary hospitals [23,24]. In the UK, the minimum and the
maximum non-ICU ward cost ($90–$784) were both obtained from
UK reference costs [26].
Further sensitivity analyses were performed to evaluate how the
results of the study change if different parametric distributions are
adopted (Weibull, lognormal and log-logistic) when estimating
survival beyond 28 days.
Monte Carlo simulations were used to explore further the
robustness of the estimated cost-effectiveness. Uncertainty in the
data was captured by fitting probability distributions to each
parameter. The Beta distribution was selected for binomial data.
All cost parameters, were assumed to follow a Gamma distribution
while a Log normal distribution was chosen for relative risk
parameters. Lastly, to reduce the uncertainty in the estimated
survival parameters, a Cholesky decomposition of the covariance
matrix was used to ensure that the parameters of Gompertz
parametric model, c and l, were appropriately correlated on a log
scale [30]. One thousand random samples were taken from all
distributions and 1,000 estimates of the incremental cost,
incremental life years saved and net monetary benefit were
simulated. The probability that TXA was a cost-effective
intervention was estimated by counting the proportion of
simulations which produced positive net monetary benefits.
Results were displayed with a cost effectiveness acceptability curve
(CEAC) that shows the probability that the intervention is cost
effective for different willingness-to-pay values for a life year saved.
Results
Base case analysis
Giving TXA increases costs because of the TXA administration
cost and the longer non-ICU hospital stay (Table 2). The
incremental cost of TXA per 1,000 patients is $18,025, $20,670
and $48,002 in Tanzania, India and the UK respectively (Table 2).
The incremental cost of giving TXA is lower in Tanzania because
both the personnel cost for administering the drug and the unit
cost of non-ICU day are lower. As expected, the incremental cost
of TXA is higher in the UK, where administering the drug to 1000
trauma victims would cost $30,830.
Life years saved were estimated taking into account the age
distribution of the trauma patients. The number of life years saved
depends on both the baseline risk of death after trauma and on the
life expectancy. TXA would save 372 LYs per 1,000 patients in
Tanzania (which has lower life expectancy but a higher baseline
risk of death). While in India TXA would save 315 LYs per 1,000
trauma patients. In the UK, where life expectancy is high, TXA
can potentially save 755 LYs per 1000 patients. The incremental
cost per life year saved is $48, $66 and $64 for Tanzania, India and
the UK respectively (Table 2).
One way sensitivity analysis
Results of one way sensitivity analysis are reported in Table 3.
In all three countries, the price of TXA has a high impact on the
cost effectiveness of the intervention. If the price of 2 g of TXA is
$2.57 the cost-effectiveness of TXA would be $8 per LY
(Tanzania), $12 per LY (India) and $26 per LY (UK). While, if
TXA unit cost is $45.6 per patient, as suggested in the study
conducted by Eaton et al. [29], TXA incremental cost per LY
saved would be $124, $148, $86 in Tanzania, India and the UK
respectively. Another important determinant of TXA cost
effectiveness is the RR reduction associated with drug adminis-
tration. If TXA was associated with a 19% reduction in the
probability of death (lower bound of the 95% confidence interval)
the incremental cost of TXA would be $33 in Tanzania, $45 in
India and $43 in the UK. Neither the cost per day spent in a
general ward, nor an increase in time spent in a general ward
affect the cost effectiveness of TXA in Tanzania and India. In the
UK, where the cost of a general ward is higher an increase in the
mean length of non-ICU hospital stay would have a greater effect
on the incremental cost-effectiveness ratio.
The selection of the parametric distribution with which to
extrapolate survival beyond study follow up can influence
significantly the results of a cost effectiveness analysis [31]. The
AICs and the Cox-Snell residual plots indicated that the Gompertz
model was the best-fitting model (e.g. the AICs were 10087
Table 1. Resource use and Unit Costs.
Resource Use and Unit Cost Tanzania India UK
Resource use
TXA dosage (gram) 2 2 2
100 ml saline bag 1 1 1
500 ml saline bag 1 1 1
Minutes spent by nurse preparing &
administering TXA
21 21 21
Average number of non-ICU days 10 7 8
Unit Cost ($)
TXA per gram 5.70 5.70 5.70
Nurse per hour 2.37 8.08 38
Syringes and needles 0.18 0.19 0.23
IV administration set 4.35 4.35 4.35
Non-ICU hospital cost per day 13 28 429
doi:10.1371/journal.pone.0018987.t001
Table 2. Cost, Effectiveness and Cost-effectiveness of TXA in
Tanzania, India and the UK.
Item Tanzania India UK
Non-ICU hospital stay ($)*
TXA 135,183 213,435 3,272,416
No TXA 134,641 212,315 3,255,244
TXA administration cost ($)*
TXA 17,483 19,550 30,830
Overall incremental cost ($)* 18,025 20,670 48,002
Life years gained discounted*
TXA 13,079 18,176 24,162
No TXA 12,707 17,861 23,407
Incremental life year saved* 372 315 755
Incremental cost per life year
saved ($)
48 66 64
*per 1,000 patients.
doi:10.1371/journal.pone.0018987.t002
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(Gompertz)). Using different parametric distributions produced
higher cumulative baseline hazards at one year and consequently
lower cost per life year saved. For instance, the incremental cost
per life year saved is $31, $37 and $34 in Tanzania, India and the
UK respectively if a Weibull parametric function were to be
adopted. The modelled gain in life years with the Gompertz model
owes very little to the extrapolation beyond 28 days, the cost per
life year saved increases from $48.4 to $48.6 (Tanzania), from
$65.6 to $65.8 (India) and from $63.5 to $63.8 (UK).
Probabilistic Sensitivity analysis
The CEACs in Figure 2 show the probability that TXA will be
cost effective for a range of willingness-to-pay values. Because of
the cost of administering the drug and the incremental non-ICU
stay, the routine administration of TXA is never a cost saving
intervention. For any given willingness to pay between $25 and
$250 there is a greater chance of TXA being cost-effective in
Tanzania than in India or the UK. Overall, TXA is likely to be a
cost effective intervention even if the willingness to pay for an
additional life year saved is as low as $100.
Discussion
This study evaluated for the first time the cost effectiveness of
giving TXA to bleeding trauma patients in the UK, India and
Tanzania, using primary data from the CRASH-2 trial which
provides the best source of scientific evidence that TXA reduces
the probability of death after trauma worldwide. This evaluation
suggests that TXA is not only life saving, as shown by the
CRASH-2 trial, but also that it is a highly cost effective
intervention if administered routinely to bleeding trauma patients
in high, middle and low income countries [2]. Early administra-
tion (within three hours) of TXA would cost $48, $66 and $64 per
LY saved in Tanzania, India and the UK respectively. According
to the WHO Commission on Macroeconomics, healthcare inter-
ventions costing less than GDP per capita per Disability-Adjusted
Table 3. One-way sensitivity analyses.
Cost per life-year
gained
Tanzania India UK
TXA drug cost
$2.57 8 12 26
$45.6 124 148 86
RR of death with TXA versus non TXA
0.81 33 45 43
0.95 126 170 168
Additional non-ICU hospital stay for TXA
patients
0.007 days 47 63 45
0.080 days 50 69 86
Cost of non-ICU hospital stay (per day)
Low unit cost 47 64 46
High unit cost 49 67 82
Parametric distribution used
Weibull 31 37 34
Lognormal 35 46 39
Log-logistic 25 42 32
doi:10.1371/journal.pone.0018987.t003
Figure 2. Cost-effectiveness acceptability curves showing the probability of TXA being cost effective in Tanzania, India and the UK.
doi:10.1371/journal.pone.0018987.g002
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[32]. DALYs are a measure of the years of life lost from disease and
years lived with a disability. According to the World Bank
classification, GDP per capita in low income countries ranges from
$380 to $975, in lower middle income countries between $976 and
$3855, upper middle income between $3,856 and $11,905 and high
income countries GDP above $11,906 [33]. Thus, if the life years
saved by TXA are spent in perfect health (one LY saved is equal to
one DALY averted) TXA is a highly cost effective intervention in all
the countries considered. The sensitivity analyses presented reinforce
this conclusion.
However, a number of limitations should be considered when
interpreting these results. It was necessary to model survival over
12 months using data for the first 28 days following the trauma
and different statistical models will produce different estimates of
benefit. However, different models were explored and the one
selected as well as providing the best fit to the data also produced
more realistic estimates of the impact on long term survival. In this
evaluation those predicted to survive the first year following the
trauma are assumed then to have the same life expectancy as
members of the general population of similar age and gender.
A related limitation is that the measure of incremental cost-
effectiveness is cost per life year gained rather than cost per
quality-adjusted life year (QALY) (a year in perfect health is
considered equal to one QALY) gained or DALY averted.
Depending on the extent to which these patients do not enjoy
perfect health, the cost per QALY gained or the cost per DALY
averted will be higher than the cost per life year saved.
A furtherpotentiallimitationisthattheanalysisdoesnotallowfor
future health service savings. CRASH-2 showed that after 28 days
the proportion of patients reporting no symptoms at discharge was
significantly higher in the TXA group (14.7%) versus placebo
(13.3%) (RR=1.11, 95% CI 1.04 to 1.19, p=0?0023) [2]. If TXA
patients are more likely to survive without disability this study
under-values the potential cost saving arising from the administra-
tion of TXA since healthier people will have lower future utilization
of health care services.
Identifying cost effective interventions to decrease the number
of injury related deaths is a major public health challenge.
According to the Disease Control Priority Project in 2001
unintentional injuries alone account for 6% of all deaths
worldwide [34]. The majority of unintentional injuries-related
deaths, more than 90%, occur every year in low and middle
income countries posing a further financial burden on these
countries’ economies and underfinanced health care systems [34].
This study suggests that TXA is a highly cost effective
intervention in three very different settings. Given that TXA is
effective and it is of relatively low cost it is not surprising that it is
cost-effective in high income settings. However, it was important to
demonstrate that it was likely to be cost-effective in countries with
much more limited health care budgets, such as in Tanzania and
India where due to the high numbers of trauma victims this simple
intervention can avert thousands of deaths every year. Further
research is needed to evaluate the effects of TXA on the quality of
life of trauma patients.
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